NAII

Business Context and Reporting Period

Company: Natural Alternatives International, Inc. (NAI)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2008
Business Overview: NAI operates in two primary segments: private label contract manufacturing (96% of sales) and branded products (4% of sales). The company manufactures nutritional supplements and health care products. During the quarter, the company executed a strategic shift to narrow its branded product focus, selling the "As We Change" catalog business and classifying the legacy Real Health Laboratories (RHL) business as discontinued operations.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. Net loss includes $1.0 million loss from discontinued operations.

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 15% year-over-year. Private label contract manufacturing sales dropped 14% due to lower volumes from a key customer (Mannatech) and unfavorable foreign currency fluctuations. Branded product sales fell 26% due to the cessation of the Dr. Cherry television program.
• Margin Compression: Gross profit margin declined 5.0 percentage points to 12%. This was driven by higher per-unit manufacturing costs, increased labor and overhead for Good Manufacturing Practices (GMP) compliance, and unfavorable currency exchange rates.
• Discontinued Operations: The company recorded a $1.0 million loss from discontinued operations, primarily due to a $0.6 million restructuring charge for severance and exit costs related to the sale of the legacy RHL business.
• Cash Flow: Net cash used in operating activities was $0.6 million, compared to $0.03 million provided in the prior year. This was offset by a $2.5 million cash inflow from reduced accounts receivable balances.

Guidance, Outlook, and Risks

• Outlook: Management anticipates a net after-tax loss in the second quarter of fiscal 2009 due to increased operating costs, unfavorable foreign currency fluctuations, and additional exit costs from the RHL divestiture.
• Debt Covenants: The company is currently not in compliance with its quarterly net income and fixed charge coverage ratio covenants. While the lender granted a waiver for the current period, the company does not expect to meet the net income covenant as of December 31, 2008, and intends to request another waiver. Consequently, all long-term debt has been reclassified as current.
• Customer Concentration: Revenue remains highly concentrated, with the two largest customers accounting for 78% of total net sales from continuing operations.
• Strategic Focus: Future efforts will focus on leveraging certified facilities for private label customers, growing the "Pathway to Healing" product line, and improving operational efficiencies.

Investor Verification Checklist

• Covenant Compliance: Verify the status of the upcoming waiver request for the December 31, 2008 net income covenant and the potential impact on debt classification.
• Customer Dependency: Monitor sales trends for the top two customers (representing 78% of revenue) to assess concentration risk.
• Discontinued Operations: Confirm the timeline and final terms for the sale of the remaining legacy RHL business operations.
• Currency Exposure: Evaluate the impact of foreign exchange fluctuations on the European subsidiary (NAIE), which contributed significantly to the operating loss.
• Liquidity Position: Assess the sufficiency of the $3.1 million cash balance and $6.6 million available credit line to fund operations through the next 12 months given the projected losses.